3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nauticus Robotics entered a Sixth Amendment to its Senior Secured Term Loan Agreement on September 30, 2026, lowering the conversion price on the loans to $1.488 for the period ending October 2, 2026. The loans were originally convertible at an initial price of $6.00, and the company has repeatedly lowered that price through a series of amendments since October 2025, which changes how many common shares the loans could convert into.
Sixth Amendment dated September 30, 2026 reduces the conversion price to $1.488 for the period ending October 2, 2026
Initial conversion price under the term loan was $6.00, subject to adjustment
Fifth Amendments, dated as of September 14, 2026, extended the maturity date to January 31, 2028
Exhibits 10.1 and 10.2 containing the amendment and collateral agent consent were filed with the report
Nauticus Robotics received two waivers from a single holder of its Series B and Series C Convertible Preferred Stock covering a Triggering Event tied to preferred shares remaining outstanding on or after September 30, 2026. The waivers run through March 31, 2027, and waive the default 18% dividend rate, incremental dividends, and the Triggering Event Conversion with its 125% multiplier, for that period only.
Waivers were executed by one holder on September 30, 2026, covering Series B and Series C Preferred Stock separately.
Waiver Period runs from September 30, 2026 through March 31, 2027.
Waived the increase to an 18% per annum default dividend rate and the 125% Conversion Amount multiplier, but not the existing 120% calculation.
Waivers bind only the signing holder; the filing does not waive other triggering events, breaches, or defaults.
Pyxis Oncology closed an underwritten public offering on October 1, 2026, selling 36,047,919 shares and pre-funded warrants for 1,883,121 shares, each paired with common warrants, for a combined price of $2.90 per share. The company expects net proceeds of about $102.8 million, and says its cash plus these proceeds will fund operations into the first half of 2028. The common warrants cannot be exercised until stockholders approve an increase in authorized shares, and if they are exercised, the company would receive about $162.2 million more, net of a 6% solicitation fee.
Offering: 36,047,919 shares and 1,883,121 pre-funded warrants, with common warrants for up to 49,310,352 shares; closed October 1, 2026
Combined public offering price of $2.90 per share; common warrants have a $3.50 exercise price
Net proceeds of about $102.8 million; up to about $162.2 million more if all warrants are exercised, net of a 6% fee
Warrants require a stockholder vote to increase authorized shares, with a meeting planned within 60 days of closing; the company says funds may be insufficient for the Phase 3 Headliner trial if warrants go unexercised
Workday entered a new Credit Agreement on October 1, 2026, replacing its prior $1.0 billion revolving credit facility. The new facility provides up to $1.5 billion in revolving credit, and Workday had no revolving loans outstanding as of that date. The filing describes the facility's pricing, covenants, and maturity, which give Workday a larger committed borrowing source.
New revolving credit facility totals $1.5 billion, up from $1.0 billion under the prior agreement dated April 6, 2022
No revolving loans were outstanding as of October 1, 2026
Facility matures October 1, 2031, with up to two requests to extend by one year
Financial covenant requires a maximum leverage ratio of 3.50 to 1.00, with a step-up to 4.50 to 1.00 after a Qualified Acquisition
Veritone, Inc. disclosed a registered direct offering of 20,000,000 shares of its common stock to named purchasers under a securities purchase agreement dated September 30, 2026. The filing attaches a legal opinion from Cooley LLP and does not state the offering price or proceeds, so the dilution and cash impact cannot be determined from this document.
Offering of 20,000,000 shares of common stock at $0.001 par value to named purchasers
Securities purchase agreement entered into September 30, 2026
Made under Form S-3 registration statement No. 333-280148, effective June 21, 2024
Exhibit 5.1 is a Cooley LLP opinion dated October 1, 2026
Two indirect subsidiaries of SharonAI Holdings signed a $356 million senior secured term loan facility on September 28, 2026, to finance GPU servers and data center infrastructure for a customer contract. The parent company guarantees the loans on a limited, releasable basis, and the filing says the financing becomes non-recourse to the parent after Facility A is repaid. Shareholders should note the debt carries fixed interest rates of 7.25% to 9.95% and a 42-month maturity, with a change of control and customer contract default treated as review events.
Facilities total up to US$356 million: Facility A up to US$150 million and Facility B up to US$206 million.
Facility A bears an initial 7.25% fixed rate that rises to as high as 9.95%; Facility B bears a fixed 9.95% rate.
Each facility matures 42 months after first utilization, and the Company guarantees the Borrowers' payment obligations through a releasable guarantee deed poll.
The press release says Jarden Australia was sole financial advisor and arranger, and names Goldman Sachs among the investors.
PBF Holding Company, a subsidiary of PBF Energy, entered into an amended and restated asset-based revolving credit agreement on September 30, 2026, with Bank of America as administrative agent. The facility replaces the existing agreement dated August 23, 2023, and offers a maximum commitment of $4.0 billion. The filing says the new facility carries reduced commitment fees on unused amounts, while interest rates and letter of credit fees are generally consistent with the prior agreement.
Maximum commitment of $4.0 billion under the 2026 Revolving Loan
Maturity date of September 30, 2031
Reduced commitment fees on the unused portion compared with the Existing Credit Agreement
Interest rates and letter of credit fees generally consistent with the prior agreement
Quaker Chemical entered into an amendment to its credit agreement on October 1, 2026, creating a new $550 million seven-year term loan B facility. Proceeds will repay in full the U.S. Term Loans outstanding under the existing agreement, and the company said the deal extends its debt maturity profile and reduces required annual debt payments.
$550 million term loan B facility matures October 1, 2033
Interest at Term SOFR plus 1.750% for Term SOFR loans; quarterly amortization of 0.25% of initial principal
Proceeds repay in full the U.S. Term Loans; their aggregate principal balance is $0 as of the amendment's effective date
Facility is secured by first priority liens on substantially all assets and carries a 1.00% prepayment premium for a repricing event within six months
Accelevation Holdings Corp. completed its initial public offering of Class A common stock, with the company selling 10,000,000 shares and selling stockholders selling 20,000,000 shares at $18.00 per share, closing on October 1, 2026. The filing also reports seven new directors, amended charter and bylaws, and new agreements governing the company's structure, which shape how existing owners and new public shareholders are related.
Firm offering: 10,000,000 shares sold by the company and 20,000,000 by selling stockholders at $18.00 per share; underwriters hold a 30-day option for up to 4,500,000 more shares
Seven directors appointed September 29, 2026, including Manu Bettegowda, Matt Bujor and Michael Rubiera-linked director nomination rights
Amended and restated certificate of incorporation and bylaws effective September 29, 2026; 116,965,529 Class B shares issued to Investment Holdings
Fortress Biotech repaid in full the remaining $15.0 million of principal on its Oaktree senior secured credit facility on September 30, 2026, plus about $435,000 of accrued interest, a $150,000 prepayment fee and other closing costs. With the repayment, the debt is satisfied, liens on company property are released, and the Oaktree Agreement terminated automatically.
Principal repaid: $15.0 million on September 30, 2026, with the facility originally a $50.0 million senior secured credit agreement dated July 25, 2024
Additional payments: about $435,000 in accrued interest and a $150,000 prepayment fee, plus other closing costs
Upon repayment, all liens securing the facility were released and the Oaktree Agreement terminated
OpenText issued $1.0 billion of senior secured notes due 2031 and 2033 on October 1, 2026, and extended its revolving credit facility maturity from December 19, 2028 to October 1, 2031. Proceeds, with cash on hand, are earmarked to redeem its $1.0 billion 6.900% notes due 2027 and to fund a tender offer for up to $300 million of its 3.875% notes due 2028, with settlement expected October 2, 2026.
Two $500 million note tranches: 6.700% due October 15, 2031 and 7.150% due October 15, 2033
Proceeds plus cash on hand to redeem all $1.0 billion of 6.900% senior secured notes due 2027
Tender offer for up to $300 million of 3.875% senior notes due 2028; both transactions expected to settle October 2, 2026
Revolver maturity extended from December 19, 2028 to October 1, 2031
Solaris Energy Infrastructure issued $1.25 billion of 7.000% senior notes due 2032 in a private placement on October 1, 2026, with net proceeds of about $1,227.2 million. The company also raised its revolving credit facility commitments by $200.0 million to $850.0 million. The new debt adds to the company's borrowings, and the filing says proceeds are for general corporate purposes, growth capital expenditures and offering fees.
$1.25 billion of 7.000% senior notes due April 1, 2032, issued October 1, 2026
Net proceeds of approximately $1,227.2 million after initial purchasers' discount and estimated expenses
Revolving credit facility commitments increased from $650.0 million to $850.0 million; letter of credit sublimit raised to $325.0 million
Notes are senior unsecured guarantees by the parent and subsidiary guarantors; redemption at 103.500% from April 1, 2029 at the earliest
Universal Logistics Holdings' subsidiaries signed a Fourth Amendment to their credit agreement with KeyBank on September 29, 2026. The amendment extends the facility's maturity to September 30, 2029 and lowers aggregate revolving commitments from $500.0 million to $350.0 million, while allowing an uncommitted increase of up to $150.0 million.
Maturity extended from September 30, 2027 to September 30, 2029
Aggregate revolving commitments reduced from $500.0 million to $350.0 million
Accordion feature allows up to $150.0 million in increases, subject to conditions and lender commitments
Interest-rate margins and unused commitment fees tied to revised leverage-based pricing grids
On September 28, 2026, Grand Canyon Education entered a five-year, $100.0 million senior secured revolving credit facility with Zions Bancorporation, N.A. dba National Bank of Arizona as administrative agent. The company intends to use borrowings mainly to fund stock repurchases and for general corporate purposes, and the facility carries covenants and default triggers that shareholders should note, including a delisting event of default.
$100.0 million five-year senior secured revolving facility dated September 28, 2026; includes a $10.0 million letter of credit sublimit
Borrowings intended primarily to fund repurchases of common stock under the board-approved repurchase program
Interest at one-month Term SOFR plus a margin of 1.50% to 2.00% based on leverage; quarterly unused fee of 0.0625%
Covenants require minimum fixed charge coverage of 1.10 to 1.00 and maximum leverage of 2.00 to 1.00; capital expenditures capped at $50.0 million per fiscal year
On September 30, 2026, Century Communities amended its Credit Agreement with U.S. Bank National Association as administrative agent. The amendment increases total lender commitments to $1.2 billion, adds Flagstar Bank and Morgan Stanley Senior Funding as lenders, and extends the facility termination date for extending lenders to November 1, 2030. It also removes a 0.10% SOFR credit spread adjustment and revises the tangible net worth covenant.
Aggregate commitments increased to $1,200,000,000 under the amended Credit Agreement.
Facility termination date extended to November 1, 2030 for First Amendment Extending Lenders.
BMO Bank N.A. will be a Non-Extending Lender; Flagstar Bank, N.A. and Morgan Stanley Senior Funding, Inc. added as new lenders.
Tangible net worth covenant now requires at least approximately $1,766,519,096 plus 50% of net equity proceeds and 50% of quarterly net income after June 30, 2026.
On October 1, 2026, subsidiary DBR Land Holdings LLC completed a private placement of an additional $125 million of 6.250% senior notes due 2030, upsized from an initial $100 million offering. The company intends to use the net proceeds to repay part of its revolving credit facility borrowings, and the new notes are identical to and treated as part of the same series as the $500 million notes issued in 2025.
Additional $125 million of 6.250% senior notes due 2030 completed October 1, 2026, upsized from an initial $100 million offering
Net proceeds intended to repay a portion of outstanding revolving credit facility borrowings
New notes are part of the same series as the $500 million Existing Notes under the indenture dated November 25, 2025
Notes are guaranteed on a senior unsecured basis by existing subsidiaries; issued under Rule 144A and Regulation S, not registered
On October 1, 2026, TransCode Therapeutics made an $840,975 prepayment on its convertible notes with Yorkville under a waiver. The stock's daily VWAP was below the $1.72 Floor Price on 10 of 14 trading days from September 11 to September 30, 2026, which could have triggered monthly repayment obligations. After the prepayment, about $4.1 million of principal remains outstanding, and the waiver covers potential Amortization Events through October 31, 2026.
Prepayment of $840,975 made October 1, 2026: $759,000 principal, $75,900 prepayment premium and $6,075 accrued interest.
Yorkville waived any Amortization Event deemed to have occurred through September 30, 2026, and through October 31, 2026.
Daily VWAP was below the $1.72 Floor Price on 10 of 14 trading days from September 11 to September 30, 2026.
About $4.1 million of principal remains under the Convertible Notes after the prepayment.
Mangoceuticals' subsidiary MangoRx IP Holdings, which holds the patent portfolio behind its MGX-0024 antiviral technology, entered into subscription agreements on September 30, 2026 with two accredited investors for a combined 25% membership interest at $2.5 million. The company received $1.75 million at the initial closing, and the remaining $750,000 is due by November 28, 2026. The company states that no Mangoceuticals common stock, warrants or other parent-company securities were issued, so the deal does not increase the parent's outstanding shares.
Two accredited investors agreed to buy a combined 25% membership interest in MangoRx IP for $2.5 million.
The company has received $1.75 million so far; the second payment of $750,000 is due by November 28, 2026.
No shares of Mangoceuticals common stock, warrants or other parent-company securities were issued, according to the company.
Proceeds are to fund commercialization of the MangoRx IP patent portfolio; the filing says the deal was made without a public offering.
Nauticus Robotics obtained a waiver from one holder of its Series A Convertible Preferred Stock covering a triggering event that would otherwise arise because Series A shares remain outstanding on or after September 30, 2026. The waiver covers the period through January 31, 2027, and suspends an increased 18% dividend rate, incremental dividends, and a 125% conversion multiplier for that holder. The waiver is limited to that holder and does not affect other triggering events or the company's other preferred stock holders.
Waiver received September 30, 2026 from one Series A Convertible Preferred Stock holder
Waiver Period runs from September 30, 2026 through January 31, 2027
Waived default dividend rate of 18% per annum and the 125% Conversion Amount multiplier for the period, to the extent tied to the Specified Event
Waivers from other Series A, Series B and Series C holders are expected to contain substantially similar language with periods ending no earlier than January 31, 2027
Controlled Thermal Resources (CTR) has signed agreements with strategic investors tied to its proposed business combination with Plum Acquisition Corp. IV. About $205 million of its roughly $245 million in convertible notes is expected to convert to equity at closing, and about $40 million is expected to convert into a planned PIPE financing. The company says this will simplify its capital structure before the combined company lists on Nasdaq as CTRH, with closing expected in the fourth quarter of 2026, subject to shareholder and regulatory approvals.
About $205 million of convertible notes expected to convert to equity at closing
About $40 million expected to convert into the new planned PIPE financing
Convertible notes expected to total about $245 million at closing, held by strategic investors
Proposed Transactions expected to close in Q4 2026; combined company to trade on Nasdaq as CTRH
On September 25, 2026, USBC signed an unsecured promissory note with Goldeneye 1995 LLC allowing advances of up to $22.0 million at 8.5% annual interest, maturing September 25, 2029. The filing says Goldeneye is solely owned and managed by Chairman and CEO Robert Gregory Kidd, who holds a majority of the voting power, making this a related-party transaction that shareholders should weigh against the terms.
Advances of up to $22.0 million; no amounts had been drawn as of the filing date.
Interest of 8.5% per annum, payable quarterly beginning December 31, 2026; maturity September 25, 2029.
After an event of default, the rate may rise to 11.5% per annum and amounts may become immediately due.
Goldeneye is solely owned and managed by Chairman and CEO Robert Gregory Kidd, who holds a majority of voting power.
On October 1, 2026, VirnetX entered into an at-the-market offering agreement with Titan Partners Securities LLC as sales agent, under which it may sell up to $19,135,717 of common stock from time to time. The company is not obligated to sell any shares, and it intends to use any net proceeds for product development, marketing and general corporate purposes.
Sales agreement dated October 1, 2026 covers up to $19,135,717 of common stock, sold through Titan Partners Securities LLC.
The company will pay the agent a commission of 3.0% of the gross sales price of shares sold.
Shares are offered under a Form S-3 shelf registration (File No. 333-295960) and a prospectus supplement dated October 1, 2026.
Proceeds, if any, are intended for product development, marketing and general corporate purposes.
Veritone agreed on September 30, 2026 to sell 20,000,000 shares of common stock to purchasers in a registered direct offering, with expected gross proceeds of $15.0 million before offering expenses. The company plans to use the net proceeds, together with existing cash, to repay or restructure part of its convertible debt and for working capital, and the forward-looking statements cite its 1.75% convertible senior notes due November 2026. The new shares add to the existing share count, while the filing says the proceeds are intended to address debt maturing later this year.
Issuance of 20,000,000 shares of common stock at $0.001 par value under an effective Form S-3 shelf registration
Expected gross proceeds of $15.0 million before offering expenses
Closing expected on or about October 2, 2026, subject to customary closing conditions
Proceeds intended to repay or restructure part of convertible debt, including 1.75% convertible senior notes due November 2026 referenced in the filing
Chesapeake Utilities established an at-the-market equity offering program that allows it to sell common stock with an aggregate sales price of up to $225 million through several banks and forward sale agreements. The filing states that any sales are at the company's discretion and that proceeds, if any, would go to general corporate purposes, including capital expenditures and repayment of short-term debt.
Program covers up to $225,000,000 of common stock, dated September 30, 2026 agreement and October 1, 2026 press release
Commissions for managers are up to 2.0% of gross sales price per share; forward sellers receive up to 2.0% commission
Company expects no initial proceeds from borrowed shares sold by forward sellers; proceeds would come on future physical settlement
Offering is registered under shelf registration No. 333-299198 via prospectus supplement dated September 30, 2026
FrontView REIT reported third quarter investment activity: it bought 16 properties for $50.6 million at a 7.6% cash yield and sold 5 occupied properties for $17.1 million at a 6.6% cash yield. It also raised capital through at-the-market common stock sales and Series A Convertible Preferred Stock, which may affect per-share figures for shareholders.
Third quarter: 16 properties acquired for $50.6 million (7.6% cash yield); 5 occupied properties sold for $17.1 million (6.6% cash yield)
Year to date: 43 properties acquired for $142.6 million (7.5% cash yield); 20 properties sold for $49.7 million
Third quarter common stock: 1,699,165 shares issued and settled under the at-the-market program for net proceeds of $32.7 million
Series A Convertible Preferred: $20.0 million issued in the quarter, bringing total drawn to $45.0 million of $75.0 million capacity; further draw anticipated November 10, 2026
Innovative Industrial Properties, through a subsidiary, agreed on September 28, 2026 to increase a mezzanine loan to IQHQ affiliates by $267.0 million, bringing the maximum principal to $400.0 million, with $245.0 million provided by the company. The loan supports the Alewife Park life science campus in Cambridge, Massachusetts, and the company said in its press release it expects the investment to add to earnings and increase its life science exposure.
Company subsidiary provides up to $245.0 million under Note B; about $111.0 million was funded at closing to repay a $85.0 million bridge loan
Remaining about $134 million is expected to be funded through the fourth quarter of 2027, subject to conditions
Interest rate is the greater of 14% or a benchmark plus a 9.0% spread; press release expects about 15.8% over the loan term
Maturity extended to February 9, 2028, with a second one-year extension option; company may also buy up to $155 million of another lender's notes
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.